JP2023534206A5 - - Google Patents

Info

Publication number
JP2023534206A5
JP2023534206A5 JP2023501477A JP2023501477A JP2023534206A5 JP 2023534206 A5 JP2023534206 A5 JP 2023534206A5 JP 2023501477 A JP2023501477 A JP 2023501477A JP 2023501477 A JP2023501477 A JP 2023501477A JP 2023534206 A5 JP2023534206 A5 JP 2023534206A5
Authority
JP
Japan
Prior art keywords
mol
lipid
formulation according
nucleic acid
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040913 external-priority patent/WO2022011156A1/en
Publication of JP2023534206A publication Critical patent/JP2023534206A/ja
Publication of JP2023534206A5 publication Critical patent/JP2023534206A5/ja
Pending legal-status Critical Current

Links

JP2023501477A 2020-07-10 2021-07-08 肺に治療薬を送達するための脂質ナノ粒子 Pending JP2023534206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050594P 2020-07-10 2020-07-10
US63/050,594 2020-07-10
PCT/US2021/040913 WO2022011156A1 (en) 2020-07-10 2021-07-08 Lipid nanoparticles for delivering therapeutics to lungs

Publications (2)

Publication Number Publication Date
JP2023534206A JP2023534206A (ja) 2023-08-08
JP2023534206A5 true JP2023534206A5 (cg-RX-API-DMAC7.html) 2024-07-03

Family

ID=79552114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501477A Pending JP2023534206A (ja) 2020-07-10 2021-07-08 肺に治療薬を送達するための脂質ナノ粒子

Country Status (10)

Country Link
US (1) US20240065982A1 (cg-RX-API-DMAC7.html)
EP (1) EP4178585A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534206A (cg-RX-API-DMAC7.html)
KR (1) KR20230038217A (cg-RX-API-DMAC7.html)
CN (1) CN115768438A (cg-RX-API-DMAC7.html)
AU (1) AU2021305214A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188661A1 (cg-RX-API-DMAC7.html)
IL (1) IL299750A (cg-RX-API-DMAC7.html)
MX (1) MX2023000511A (cg-RX-API-DMAC7.html)
WO (1) WO2022011156A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019376006B2 (en) 2018-11-09 2026-07-02 Arbutus Biopharma Corporation Cationic lipids containing silicon
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
WO2024086929A1 (en) * 2022-10-25 2024-05-02 Nanovation Therapeutics Inc. Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
WO2025133951A1 (en) * 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
CN118576568B (zh) * 2024-08-06 2024-11-26 北京悦康科创医药科技股份有限公司 一种药物组合物及其制备方法和应用
CN121622610A (zh) * 2024-09-05 2026-03-10 苏州慧疗生物医药科技有限公司 向细胞内递送遗传物质的三组分脂质纳米颗粒及组合物
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279254B1 (en) * 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
ES2898340T3 (es) * 2015-07-09 2022-03-07 Insmed Inc Composiciones y métodos para tratar neumopatías y lesión pulmonar
GB2596224B (en) * 2018-06-19 2022-09-07 Univ Texas Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
DE102018127300A1 (de) * 2018-10-31 2020-04-30 Henkel Ag & Co. Kgaa Wirkstoffzusammensetzung zum Schutz künstlich gefärbter Haare
AU2019376006B2 (en) * 2018-11-09 2026-07-02 Arbutus Biopharma Corporation Cationic lipids containing silicon
WO2020219941A1 (en) * 2019-04-26 2020-10-29 Genevant Sciences Gmbh Lipid nanoparticles

Similar Documents

Publication Publication Date Title
EP2567693B1 (en) Lipid encapsulated interfering RNA
US9080186B2 (en) Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
US9074208B2 (en) Modified siRNA molecules and uses thereof
US9181295B2 (en) Cationic lipids with various head groups for oligonucleotide delivery
US7838658B2 (en) siRNA silencing of filovirus gene expression
US20070218122A1 (en) siRNA silencing of influenza virus gene expression
JP2022501064A5 (cg-RX-API-DMAC7.html)
EP3877001A1 (en) Cationic lipids containing silicon
TW202539707A (zh) 用於治療b型肝炎之治療組成物及方法
US20240050463A1 (en) Therapeutic compositions and methods for treating hepatitis b
JP2023518944A5 (cg-RX-API-DMAC7.html)
HK40115528A (en) Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof
HK40115528B (en) Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof
HK1123751B (en) Lipid encapsulated interfering rna